Use este identificador para citar ou linkar para este item:
Título : Fenofibrate prevents orotic acid--Induced hepatic steatosis in rats
Autor: Ferreira, Adaliene Versiani Matos
Parreira, Gleydes Gambogi
Porto, Laura Cristina Jardim
Mario, Érica Guihen
Delpuerto, Helen Lima
Martins, Almir Sousa
Botion, Leida Maria
Palavras-chave: Hepatic steatosis
Lipid metabolism
Adipose tissue
Publicador: Elsevier
Data da publicação: 16-Fev-2008
Referência: FERREIRA, A. V. et al. Fenofibrate prevents orotic acid--Induced hepatic steatosis in rats. Life Sciences, [S.l.], v. 82, n. 15-16, p. 876-883, Apr. 2008.
Abstract: The experiments performed in this report were designed to investigate the mechanisms involved in the metabolic alterations associated with orotic acid-induced hepatic steatosis and the effect of fenofibrate, a stimulant of peroxisome proliferators-activated receptor alpha (PPARalpha), on these alterations. Male Wistar rats were divided into three experimental groups: 1) fed a balanced diet (C); 2) fed a balanced diet supplemented with 1% orotic acid (OA); 3) fed OA diet containing 100 fenofibrate (OA+F), for 9 days. Administration of OA to rats induced significant increase in the hepatic total lipids content, marked microvesicular steatosis and decrease in plasma lipids concentrations compared to control group. Fenofibrate treatment prevented fatty liver induction, caused an additional reduction on plasma lipids concentrations and caused a 40% decrease in the lipogenic rate in adipose tissue. The results also showed a 40% increase in lipoprotein lipase (LPL) activity in adipose tissue from OA treated group and fenofibrate administration induced a 50% decrease in LPL activity. The liver mRNA expression of PPARalpha and ACO (acyl CoA oxidase) were 85% and 68% decreased in OA group when compared to control, respectively. Fenofibrate treatment increased the PPARalpha and ACO expressions whereas the CPT-1 (carnitine palmitoyl transferase-1) expression was not altered. Our results have shown that fenofibrate treatment decreases the hepatic lipid content induced by OA which is mediated by an important increase in fatty acid oxidation consequent to an increase in hepatic mRNA expression of PPARalpha and ACO.
Idioma: en
Aparece nas coleções:DCA - Artigos publicados em periódicos

Arquivos associados a este item:
Não existem arquivos associados a este item.

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.